Radiation Dose from PET Radiopharmaceuticals
| Age (y)/mass (kg) | |||||
|---|---|---|---|---|---|
| Radiopharmaceutical | 1/9.7 | 5/19.8 | 10/33.2 | 15/56.8 | Adult/70 |
| 18F-FDG* | |||||
| Administered activity | 51.3 | 105 | 176 | 301 | 370 |
| Bladder wall | 73.2 | 79.3 | 86.6 | 99.7 | 95.7 |
| Effective dose | 8.0 | 8.3 | 8.4 | 9.2 | 9.0 |
| 18F-NaF* | |||||
| Administered activity | 20.7 | 41.8 | 70.3 | 120 | 148 |
| Bladder wall | 27.9 | 30.2 | 33.0 | 37.9 | 36.5 |
| Effective dose | 3.0 | 3.1 | 3.2 | 3.5 | 3.4 |
| 18F-DOPA† | |||||
| Administered activity | 51.3 | 105 | 176 | 301 | 370 |
| Bladder wall | 36.9 | 40.5 | 43.9 | 50.2 | 48.4 |
| Effective dose | 4.8 | 5.3 | 5.7 | 6.5 | 6.3 |
| 82Rb* | |||||
| Administered activity | 251 | 513 | 860 | 1,471 | 1,813 |
| Thyroid | 108 | 112 | 82.5 | 91.2 | 68.9 |
| Effective dose | 8.3 | 9.2 | 8.6 | 9.9 | 8.7 |
↵* Estimates based on ICRP publication 80 (18).
↵† Estimates based on OLINDA and Brown et al. (19).
For each radiopharmaceutical, weight-based administered activity is given in megabecquerels. Also listed are dose to critical organ (organ receiving highest dose) in milligrays and effective dose in millisieverts.